Ashok Srivastava

Medical Oncologist & Chief Medical Officer

ARKAYA PHARMA, USA


Dr. Ashok Srivastava is  Chief Medical Officer of Arkaya Pharmaceutical, New Jersey, USA , Board Members of  Alpha Clinical,  New Jersey, USA,  Chairman , Founder  of Global Pharmatek Oncology, USA, Chief Medical Officer, and  Chief Medical Officer of CareBeyond - A Radiation Cancer Center in USA. He has more than 15 years of experience in cancer drug development  including radiopharmaceutical ; Phase I – 4, and marketing commercialization of  Hematology, Oncology and radiopharmacetuical drugs in USA and EU. He is leader in Cancer Drug Development  Worldwide  large Phase 2 and 3 Clinical Trials in many countries.  He  contributed to 21-INDs and 7-NDAs of Cancer Drugs and supportive care, acquisition /merger of company  and drug  for more than $225 million .  He received his clinical, medical training  & worked at renowned medical centers and pharmaceutical institutions worldwide; Walter Reed Army Institute of Research and Medical Center,  Daiichi, Sumitomo, Pharmacia, Pfizer,  Sopherion Oncology. He received his  Clinical, Medical & Business educations from All India Institute of Medical Sciences, New Delhi, India ; Academy of Medical Sciences, Czechoslovakia; School of Medicine Nagasaki University, Nagasaki, Japan, and Pharmaceutical Business at Rutgers University Business Management, New Jersey, USA. He played key role in dramatic expansion of oncology and Psychiatry drug – developed cancer drugs- Sutent (Sunitinib), Evoxac (Cevimeline HCl), and liposomal doxorubicin (Myocet) in combination with Herceptin & Paclitaxel for HER2 positive metastatic breast cancer patients and  latuda (Lurasidone) for schizophrenia and bipolar.  He is one of the inventors of Japanese encephalitis vaccine (IXIARO) .  He has published more than 85 papers in National and International medical Journals, more than 120 abstracts, 3 book chapters and 2 patents. He is recipient of numerous National & International prestigious medical awards and recognitions from United Nations, Ministry of  Health, Japan, and Department of Army, Walter Reed Army Medical Center and Walter Reed Army Institute of Research, Washington DC, USA. He served as medical advisor  to Poniard Pharmaceutical for small cell lung cancer in USA, European countries and India. Dr. Srivastavais member of numerous prestigious organizations; Americas Top Oncologist of the years 2007, 2008, 2011 Breast Cancer Foundation , Indian Society of Oncology, American Society of Clinical Oncology, American Society for Therapeutic Radiology & Oncology, American Association of Cancer Research, and International Society of Lung Cancer.  Dr. Srivastava is a strategic  medical advisor and Board Member to several biotech pharma in USA for clinical, regulatory  and supervises cancer drug development . Recently Dr. Srivastava was awarded membership of Japan External Trade  Organization, USA. Dr.Srivastava is also Board Member of  IT –Life Sciences companies engaged in Oncology clinical and technology services.  Dr. Srivastava is a Leader in Drug Safety, pharmacovigilance of  hematology, Oncology and built a global drug safety and pharmacovigilance firms in USA, and India. Dr. Srivastavawas invited as an honorable speaker at 7th  drug safety & Pharmacovigilance  congress in London, UK , China and India in Jan 2012 and 2013.  Dr. Srivastava brought 2 cancer drugs & a vaccine in global market f or  approx  3 – 3.5 billion $ global sales.  He serves as board of director for oncology virtual companies in USA for acquisition and merger.